Clinical Trial Detail

NCT ID NCT03801369
Title Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Durvalumab + Olaparib

Age Groups: senior adult

No variant requirements are available.